Top Biotech Companies in Raleigh, NC (43)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising at a double‑digit pace across 2025 and into 2026, with consistent year‑over‑year gains. Galleri test volumes and screening revenue also increased, signaling sustained commercial momentum.
Market Expansion: Access is broadening through major EHR integrations and a growing provider network, alongside initiatives to enter new geographies. These moves extend reach beyond core channels and support continued adoption.
Investor Backing & Capital Strength: Capital raises and a sizable cash position provide a multi‑year runway to fund commercialization, trials, and regulatory efforts. Strategic financings with prominent partners reinforce the ability to invest through scale‑up.
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.
Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.
Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.
Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs. With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed...
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with...
Roche's Top Stability & Growth Strengths
Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.
Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.
Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers
Quanticate is a leading global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. As experts in clinical data, Quanticate provides high quality teams that offer efficient outsourcing solutions for: • Clinical Data Management • Biostatistics • SAS Programming • Data quality oversight via Centralized Statistical Monitoring • Medical writing • Pharmacovigilance Quanticate can offer study level support, functional service provision...
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives,...
Align Technology's Top Stability & Growth Strengths
Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.
Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.
Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together...
Syneos Health's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials and third‑party recognition portray a fully integrated CRO/CCO with leadership status, including widespread involvement in recent FDA/EMA novel therapies and recognition as a leading pharmacovigilance provider.
Strategic Partnerships: Recent collaborations with Microsoft and KX are positioned to enable AI‑driven efficiencies across clinical and commercial operations, with reported improvements in cycle times supporting operational scalability.
Investor Backing & Capital Strength: The 2025 take‑private by investment groups (including Elliott and Veritas) provides financial sponsorship to pursue tech‑enabled growth and operational repositioning.
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at...
Biogen's Top Stability & Growth Strengths
Product Line Growth: “Growth” medicines (e.g., Leqembi, Skyclarys, Zurzuvae, Qalsody) rose in 2025 and continued expanding in late 2025, indicating newer products are increasingly contributing to results. Leqembi and Skyclarys are specifically described as notable growth drivers, with ongoing lifecycle work (e.g., more convenient maintenance and subcutaneous dosing) supporting momentum.
Strong Market Position & Advantage: Biogen is positioned as a focused neurology frontrunner, leading or co-leading in select high-need niches such as early Alzheimer’s (with Eisai) and rare neurologic diseases (e.g., Friedreich’s ataxia; SOD1-ALS). Its neurology clinical and commercial infrastructure is described as providing scale and credibility that helps execute complex launches.
Strategic Partnerships: The Eisai partnership on Leqembi keeps Biogen at the forefront of disease-modifying Alzheimer’s therapy while reducing risk and capital intensity through shared economics and co-commercialization. Traditional FDA approval and broader Medicare coverage also supported access, reinforcing the partnership’s ability to translate regulatory wins into commercial opportunity.
Syngenta Group is a leading global agricultural technology (AgTech) company headquartered in Basel, Switzerland. With over 50,000 employees across more than 90 countries, it provides farmers with innovative technology and expertise to increase productivity and ensure the growth of healthy, affordable, and sustainable food. The company is a world market leader in sustainable agriculture, offering a diverse portfolio of seeds...
Forma is in the biotech, pharma and other life sciences sectors make the complex compelling, treatment recommendations that are tailor-made.
GeneBiology develops a patented new drugs for serious diseases using the 505(b)(2) regulatory pathway.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
Glycan Therapeutics develops drug therapies based on a novel synthetic carbohydrate technology platform.
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.
Performs research and development on innovative therapeutics for multiple rare and infectious diseases.
Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD). Pathalys was created in partnership with Catalys Pacific and DaVita to become a multi-asset pharmaceutical company focused on the needs of patients with end-stage renal disease.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
